Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Registry ID

EUCTR2015-004436-34

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma AG

Start date

2016-09-09

Completion date

2018-09-25

Last update

2026-08-16

Conditions

• Cluster headache

Summary

To assess headache response of single subcutaneous s.c. dose of SOM230 compared to placebo in managing cluster headache attack at 30 minutes post-dosing.

Locations

• , , UK
• , , Germany

View on source registry